Clinical Phase Progression Index
Dataset snapshot: 690 therapy developers (Updated May 22, 2026)
RNA/Oligonucleotides
1.22 Rapid Scaling
Late-to-Early Phase Ratio
Gene Therapy
0.92 Steady
Late-to-Early Phase Ratio
Cell Therapy
0.69 Reduced Velocity
Late-to-Early Phase Ratio
Phase Distribution by Modality
Volume of trials in Early (Phase 1/2) vs Late (Phase 2/3) stages.
Active Architecture™ Intelligence
Targeting Alert: Cell Therapy
393 trials remain concentrated in Phase 1 / Early Phase 1. High demand projected for Phase 2 scaling infrastructure, GMP automation, and COGS reduction.
Velocity Alert: RNA
RNA/Oligonucleotides demonstrate the highest pipeline progression velocity. Target these developers for commercialization and robust supply chain solutions.